AC Immune Drops ACI-91 on Phase II Alzheimer's Failure
By Cormac Sheridan
Thursday, January 31, 2013
The drug development graveyard that is Alzheimer's disease has claimed yet another victim. This time it's AC Immune SA's ACI-91, a drug that had offered a new approach to tackling this most intractable of diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.